【レポートの概要（一部）】
1. Executive Summary
1.1 Overview
1.2 Review of the Vaccine Manufacturing Technology and Services Market
1.3 Aims, Scope and Format of Report
1.4 Research and Analysis Methods
2. Introduction to the Vaccine Market
2.1 What Are Vaccines?
2.2 The History of the Vaccine Market
2.3 The Vaccine Contract Manufacturing Market
2.3.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
2.3.2 Reasons to Outsource
2.3.3 Benefits of Outsourcing
2.3.4 The Challenges in Outsourcing Vaccine Manufacturing
2.3.5 Why Should Companies Outsource Vaccine Manufacturing?
2.3.6 Strategic Outsourcing vs. Tactical Outsourcing
2.3.7 Virtual Companies
2.3.8 Contract Manufacturing Organisations (CMOs)
2.3.9 Manufacturing Services Offered by CMOs
2.3.10 Vaccine Manufacturing Activities Typically Outsourced
3. Vaccine Manufacturing Technologies 2014
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift Towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago’s Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax’s Sf9/BV Technology
3.2.6.2 Protein Sciences Corporation (PSC): First Egg-Free Influenza Vaccine
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Leading Pre-Filled Vaccine Products 2014
3.5.3 Drivers and Restraints for Pre-filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges with Some Flu Vaccine
3.5.4.3 Novartis’ Agriflu and Fluad Ban is Lifted
3.5.4.4 Baxter Flu Vaccine and Side Effects
3.5.4.5 Reported Shelf Life Issues of Some H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.7 Cell Media Can Improve Virus Yield
4. The Vaccine Market 2014-2024
4.1 The Global Vaccine Market, 2014-2024
4.2 The Global Vaccine Market By Submarket, 2012 and 2013
4.3 The Global Vaccine Market by Submarket, 2014-2024
4.4 The Paediatric Vaccine Submarket Forecast, 2014-2024
4.4.1 Growth of Paediatrics Vaccines is Driven by Prevnar’s Blockbuster Success
4.4.2 Paediatric Vaccines: The Biggest Segment, but the Least Dynamic
4.4.3 Paediatric Vaccine Pipeline
4.5 The Adult Prophylactic Vaccine Submarket Forecast, 2014-2024
4.5.1 Adult Vaccination: Low Uptake
4.5.2 Gardasil Represented Nearly a Fifth of Segment Revenues in 2012
4.5.3 Adult Prophylactic Vaccines: Extensive Pipeline, but Still Needs to Become More Widely Established
4.5.4 Adult Prophylactic Vaccine Pipeline
4.6 The Influenza Vaccine Submarket, 2014-2024
4.6.1 Influenza: Growth is Driven by Seasonal Epidemics and Global Pandemics
4.6.2 Significant Scope for Enlarging the Patient Population
4.6.3 Influenza Market: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed
4.6.4 Influenza Product Pipeline
4.7 The Therapeutic Vaccine Submarket, 2014-2024
4.7.1 Therapeutic Vaccines: the Holy Grail of Personalised Vaccines
4.7.2 Therapeutic Vaccines: On the Cusp of an Explosion or Another Vaccine Hype?
4.7.2.1 Underperformance: Provenge is the First and Only FDA Approved Cancer Vaccine
4.7.2.3 Biovac ID Completes Phase III for Cancer Vaccine
4.7.3 Anti-Allergy Vaccines Make Up Bulk of Segment in 2013
4.7.3.1 Canada Gives Merck & Co. its First Approval for Grass Allergy Vaccine Tablet
4.7.3.2 Therapeutic Vaccine Product Pipeline
5. The Global Vaccine Contract Manufacturing Market 2014-2024
5.1 Global Vaccine Contract Manufacturing: A Tiny Fraction of The Total Vaccine Market
5.2 The Vaccine Contract Manufacturing Market Forecast: High Growth Rates from 2014-2024
5.2.1 Trends in the Vaccine Contract Manufacturing Forecast
5.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.3.1 The Leading National Markets for Vaccine Contract Manufacturing: Largely Dictated by the Local Vaccine Market
5.3.2 The Leading National Markets for Vaccine Contract Manufacturing, 2012 and 2013
5.3.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.4 The US Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5 The Japanese Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5.1 CMO’s in Japan
5.6 The EU5 Vaccine Contract Manufacturing Market, 2012 and 2013
5.6.1 The EU5 Vaccine Contract Manufacturing Market, 2014-2024
5.6.2 The French Vaccine Contract Manufacturing Market, 2014-2024
5.6.3 The German Vaccine Contract Manufacturing Market, 2014-2024
5.6.4 The Italian Vaccine Contract Manufacturing Market, 2014-2024
5.6.5 The Spanish Vaccine Contract Manufacturing Market, 2014-2024
5.6.6 The UK Vaccine Contract Manufacturing Market, 2014-2024
5.7 The Brazilian Vaccine Contract Manufacturing Market, 2014-2024
5.8 The Russian Vaccine Contract Manufacturing Market, 2014-2024
5.9 The Indian Vaccine Contract Manufacturing Market, 2014-2024
5.10 The Chinese Vaccine Contract Manufacturing Market, 2014-2024
5.10.1 Vaccine Manufacturing: Questioning China’s Regulatory Standards
6. The Leading Vaccine Contract Manufacturing Companies 2014-2024
6.1 The Vaccine Contract Manufacturing Market has Room for Consolidation
6.2 Baxter BioPharma Solutions
6.2.1 Business Capabilities
6.3 Boehringer Ingelheim
6.3.1 Recent Financial Performance
6.3.2 Boehringer Ingelheim’s Ben Venue Closure
6.3.3 Manufacturing Deals 2011-2014
6.3.4 Boehringer Ingelheim Implements Fully Disposable Biopharmaceutical Manufacturing
6.3.5 Boehringer Ingelheim Expands Biopharmaceuticals in China
6.3.6 Outlook
6.4 Catalent
6.4.1 Recent Financial Performance, 2008-2012
6.4.2 Recent Financial Performance by Segment, 2008-2012
6.4.3 Catalent Injectable Vaccines
6.4.4 Catalent Adjusts its Services
6.4.5 Future Strategies for Growth
6.4.6 Regional Market Expansion
6.5 Charles River Laboratories
6.5.1 Recent Financial Performance, 2008-2012
6.5.2 Recent Financial Performance, 3Q 2013
6.5.3 Recent Financial Performance by Segment
6.5.4 Vaccine Manufacturing Services
6.5.4.1 Vaccine Manufacturing Expansion
6.5.5 Future Outlook and Early Stage Restructuring
6.5.6 Partnerships
6.5.6.1 Partnership with AstraZeneca
6.5.6.2 Partnership with Batavia
6.6 IDT Biologika GmbH
6.6.1 Facility Expansion
6.6.2 Acquisitions and Partnerships
6.6.2.1 Acquisition of Riemser Pharma GmbH
6.6.2.2 Partnership with ImVisioN Therapeutics
6.7 Lonza
6.7.1 Recent Financial Performance, 2010-2012
6.7.1.1 Recent Financial Performance by Segment,2012
6.7.2 Manufacturing Division Restructuring
6.8 Meridian Life Science
6.8.1 Recent Financial Performance, 2008-2013
6.8.1.1 Recent Financial Performance by Segment, 2008-2013
6.8.1.2 Recent Financial Performance by Region, 2012-2013
6.9 Sigma-Aldrich
6.9.1 Revenue and Recent Performance Analysis, 2010-2013
6.9.1.1 Recent Financial Performance by Segment, 2010-2012
6.9.1.2 Segment restructuring, 2013
6.9.2 Strategy for Business Growth by Asian Expansion
6.9.3 Acquisition of BioReliance
6.9.4 Partnership with CatScl
6.10 SynCo Bio Partners
6.10.1 Recent Developments
6.10.1.1 Expansion of Facilities
6.10.1.2 FDA Approval of Partner Application
6.11 OSO BioPharmaceuticals Manufacturing
6.11.1 Facilities and Capabilities
6.11.2 New Developments
6.11.2.1 Acquisition of Catalent’s Sterile Injectables Manufacturing Business
6.11.2.2 Facility Investment
6.12 Leading Vaccine Contract Manufacturing Organisations
7. SWOT Analysis of the Vaccine Contract Manufacturing Market 2014-2024
7.1 Vaccine Contract Manufacturing Industry Trends
7.2 Strengths
7.2.1 Many Companies Cannot Afford In-house Capabilities
7.2.2 Outsourcing Improves Time to Market
7.2.3 Manufacturers get Access to Specialised Technologies
7.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
7.3 Weaknesses
7.3.1 Mass Vaccine Manufacturing is Kept In-house
7.3.2 A Highly Fragmented Vaccine Contract Manufacturing Market
7.3.3 An Unpredictable Supply and Demand Business Model
7.3.4 Lack of Differentiation in the CMO Space
7.4 Opportunities
7.4.1 Many Vaccines in the Product Pipeline
7.4.2 Therapeutic Vaccine Market could Explode
7.4.3 Emerging Market’s Growing Demand for Vaccines
7.4.3.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
7.5 Threats
7.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capitalist Funding
7.5.2 The Public are Slow to Accept Novel Technologies
7.5.3 Perception of Risk by the Original Vaccine Manufacturers
8. Expert Opinion
8.1 Interview with Dr. Eluemuno Blyden, CEO and Founder, AfriVax
8.1.1 The Egg-based Vaccine Manufacturing Myth
8.1.2 AfriVax’s New Vaccine Manufacturing Technology
8.1.3 Emerging Markets Pathing their Own Vaccine Path
8.2 Interview with Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
8.2.1 Growth of the Vaccine Contract Manufacturing Market
8.2.2 The Therapeutic Vaccine Market
8.2.3 The Use of Emerging Market Facilities
8.2.4 The Vaccine Contract Manufacturing Business Model
8.3 Interview with Dr Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
8.3.1 Vaccine Contract Manufacturing Competition
8.3.2 Target Diseases For Vaccine Development
8.3.3 Challenge Stock Vaccines
8.3.4 Meridian’s Vaccine Contract Manufacturing Revenue Stream Breakdown
8.3.5 The Changing Face of Large Pharma Drives Contract Manufacturing Growth
8.4 Interview with Dr Stefan Beyer, Managing Director, Vibalogics
8.4.1 The Benefits of Outsourcing Vaccine Manufacturing
8.4.2 The Challenges in Manufacturing Vaccines
9. Conclusion
9.1 Overview
9.2 Regulatory and Quality Standards Create High Barriers of Entry
9.3 Rich Pipeline for Therapeutic Vaccines
9.4 Emerging Markets will Show Stronger Growth
9.5 Technology Drives Changes in Manufacturing
【レポート販売概要】
■ タイトル：世界のワクチン製造技術およびサービス市場（2014-2024）■ 英文：Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024
Prospects For Leading Players
■ 発行日：2014年3月
■ 調査会社：visiongain
■ 商品コード：Visiongain-4052640
■ 調査対象地域：グローバル
- アメリカの脊柱インプラント市場2016-2020About Spine Implants in the US The spine implants help in correcting deformities of the spine and restoring the function of the spine. Some of the conditions that require the use of spine implants are spondylolisthesis, chronic degenerative disc diseases (DDDs), traumatic fracture, and other forms of spinal instability including scoliosis. These implants are mainly composed of titanium, stainless …
- m‐キシレンの世界市場：IPA（イソプロピルアルコール）及びその他用途About Meta-xylene Meta-xylene is an aromatic isomer of xylene with two methyl groups attached at the meta position of benzene. This aromatic hydrocarbon is produced by a catalyst in processes such as adsorptive separation and moving bed adsorption and crystallization. It is used for various commercial applications, most notably for the production of IPA which is used as a raw material for the prod …
- 中国の非GMO（遺伝子組み換え）食品市場2016-2020About Genetically Modified (GM) Seeds GM seeds have improved traits such as resistance to adverse environmental conditions, pests, and herbicides, and high yields. In 2015, the US dominated the global seeds market for GM seeds. Almost 40% of the world's GM crops are currently grown in the US. Monsanto held the largest share in the GM seeds market. Technavio’s analysts forecast the non-GMO food mar …
- 堅牢型ICの世界市場2018-2022About this market The global rugged IC market is growing due to increasing demand for ruggedized computers and embedded boards used in robots for mission- critical applications in the defense sector. Recent application areas wherein ruggedized computers are being used include logistics and cargo transportation, maintenance of vehicles and machinery and medical industry. Any rugged systems or solut …
- インドの個人用防護具（PPE）市場2016-2020About Personal Protective EquipmentPPE is used to ensure the safety of workers in hazardous work environments. It is deployed in a wide range of industries such as machine shop, construction, and healthcare to protect the wearer from potentially hazardous elements like airborne flying particles, fire, and biological hazards such as pathogens. The global market for these products is expected to be …
- 欧州の農業用トラクター市場2017-2021About Agriculture TractorsAn agriculture tractor is a vehicle specialized in pulling farm implements and helping in a better yield of agriculture output. Technavio’s analysts forecast the agriculture tractor market in Europe to grow at a CAGR of 1.08% during the period 2017-2021. [Covered in this report] The report covers the present scenario and the growth prospects of the agriculture tractor mar …
- 飼料添加物の世界市場：プロバイオティクス、プレバイオティクス、有機酸、精油The eubiotics market in feed has been growing rapidly in the recent years and is projected to reach a market size at USD 7.05 billion by 2020. The market is primarily driven by the growing customer attention towards superior quality feed grades, ban on antibiotics used as growth promoters in the North American and European regions, and for feed supplementation to improve nutrient utilization and n …
- Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis)：市場予測と分析（～2022）Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvemen …
- 非ホジキンリンパ腫（NHL）の疫学的予測（～2024）EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024 Summary Non-Hodgkin’s Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight infections and other diseases. NHL is characterized into three types - B-cel …
- アジア太平洋のスマート・サーモスタット市場2015-2019About Smart Thermostat A smart thermostat uses sensors to control and regulate temperature remotely or through smart devices such as smartphones, tablets, and desktops. The settings can be changed as per the time of the day. It even learns and adapts as per the daily usage of the house occupants. Technavio’s analysts forecast the smart thermostat market in APAC to grow at a CAGR of 63.98% during t …
- フレーバーヨーグルトの世界市場：フレーバー別（イチゴ、バニラ、ピーチ、ブルーベリー、その他）、流通経路別（スーパーマーケット/ハイパーマーケット、コンビニエンスストア、Eコマース、その他）、種類別（有機型、従来型）Flavored yogurt is a fermented dairy product with added flavors and has multiple health benefits. It is preferred breakfast, snack, dessert, or beverage among health-conscious consumers. The global flavored yogurt market was valued at $63.6 billion in 2018 and is anticipated to reach $92.3 billion by 2026, with a CAGR of 4.8% during the forecast period. Flavored yogurt is available in the market i …
- 航空交通管理の世界市場予測（～2022）：ドメイン別（ATC、ATFM、AIM）、最終用途別（通信、誘導、監視、自動・シミュレーション）、投資タイプ別（グリーンフィールド、ブラウンフィールド）、空港クラス別（A、B、C、D）、システム別、地域別“The air traffic management market is projected to grow at a CAGR of 11.73% during the forecast period”The growth of the Air Traffic Management (ATM) market is dependent on the upcoming Greenfield airports, expansion of existing airports, and modernization and upgradation of air traffic management systems in various countries across the world. The air traffic management market is projected to grow …
- 水質検査・分析機器の世界市場：全有機体炭素（TOC）分析計、pHメーター、溶存酸素計、伝導度計、濁度計The market for water testing & analysis is observed to be growing at a modest rate in developed economies such as Europe and North America as compared to developing regions due to the matured industrial & laboratory application sectors in the former. Laboratories are still major consumers of water testing & analysis and this application segment is expected to grow at a healthy rate. Increasing gov …
- 医療産業向けBPO（ビジネスプロセスアウトソーシング）の世界市場予測（～2021）The healthcare BPO market is projected to reach USD 276.79 Billion by 2021 from USD 170.47 Billion in 2016, growing at a CAGR of 10.2% during the forecast period (2016–2021). The pressure to reduce healthcare delivery costs, consolidation of healthcare systems, enactment of PPACA, stringent regulatory requirements, and complex clinical trial protocols are the major drivers for the healthcare BPO m …
- 購買/調達ソフトウェアの世界市場2015-2019Global Procurement Software as a Segment of Global SCM Market The procurement software is the leading segment of the SCM market, and it accounted for nearly 32% of its market share in 2014. The market for the procurement software is growing which will improve the market share in the upcoming three to four years. The others segments accounting for 68% that include warehouse management services (WMS …
